Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect PK Study of Vorolanib (CM082)
NCT04126668Phase 1Completed
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Dec 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vorolanib in Advanced Malignant Solid Neoplasm (AMSN) (2 arms), sponsored by AnewPharma Company, Ltd. Primary endpoints: Peak Plasma Concentration at 72 hours, Area Under the Plasma Concentration versus Time Curve at 72 hours and 2 more. Started Dec 2019; status: completed.
02
Drugs
vorolanib
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT04126668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126668.